Export 6089 results:
Sort by: Author [ Title  (Desc)] Type Year
A B C [D] E F G H I J K L M N O P Q R S T U V W X Y Z   [Show ALL]
Elsaid, N. M., A. E. Okasha, and A. A. Abdelghaly, "Defining and Solving the Organizational Structure Problems to Improve the Performanceof Ministry of State for Environmental Affairs-Egypt", International Journal of Scientific and Research Publications, vol. 3, no. 10, pp. 273, 2013. Abstract
Shawky, D. M., and A. F. Ali, "Defining a Measure of Cloud Computing Elasticity", International Conf. on Systems and Computer Science, France.: IEEE, 2012. Abstract
Shawky, D. M., and A. F. Ali, Defining a Measure of Cloud Computing Elasticity, : IEEE, 2012. Abstract
Din, H. S. E., R. I. Esmail, R. I. Magdy, and H. M. Lotfy, "Deferoxamine–induced dysplasia-like skeletal abnormalities at radiography and MRI", Pediatric Radiology, vol. 43, issue 9, pp. 1159-1165, 2013.
Seif El Dien, H. M., R. I. Esmail, R. E. Magdy, and H. M. Lotfy, "Deferoxamine-induced dysplasia-like skeletal abnormalities at radiography and MRI.", Pediatric radiology, vol. 43, issue 9, pp. 1159-65, 2013 Sep. Abstract

BACKGROUND: Current thalassemia major treatment includes blood transfusion and iron chelation, which is associated with growth disturbances and radiographic changes in the long bone metaphyses.

OBJECTIVE: To explore and discuss the spectrum of deferoxamine-induced bone-dysplasia-like changes in children with thalassemia major in Egypt.

MATERIALS AND METHODS: We studied 59 Egyptian children with thalassemia major and generalized arthralgia. All started deferoxamine treatment at 3 years of age. We conducted skeletal survey and MRI of both knees in radiographically positive children. Each child's age, serum ferritin, age of onset and duration of therapy were compared with the radiologic findings.

RESULTS: Twenty-two (37.3%) children had variable degrees of skeletal dysplasia-like changes similar to those described with deferoxamine intake, mostly around the knees. Mild dysplasia-like changes were seen in 4 (18%) children; moderate changes were seen in 11 (50%) children and severe changes were seen in 7 (31.8%) children. No statistically significant relationships were detected between bone changes and the children's age, age of starting deferoxamine, duration of therapy, or serum ferritin level.

CONCLUSION: A wider spectrum of deferoxamine-induced bone-dysplasia-like changes was recognized despite delayed onset and small doses of therapy. These changes should be considered as a possible cause of arthropathy in children with thalassemia major, especially symptomatic children.

Kwiatkowski, J. L., M. O. N. A. HAMDY, A. El-Beshlawy, F. S. Ebeid, M. Badr, A. Alshehri, J. Kanter, B. Inusa, A. A. M. Adly, S. Williams, et al., "Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.", Blood advances, vol. 6, issue 4, pp. 1243-1254, 2022. Abstract

Many people with sickle cell disease (SCD) or other anemias require chronic blood transfusions, which often causes iron overload that requires chelation therapy. The iron chelator deferiprone is frequently used in individuals with thalassemia syndromes, but data in patients with SCD are limited. This open-label study assessed the efficacy and safety of deferiprone in patients with SCD or other anemias receiving chronic transfusion therapy. A total of 228 patients (mean age: 16.9 [range, 3-59] years; 46.9% female) were randomized to receive either oral deferiprone (n = 152) or subcutaneous deferoxamine (n = 76). The primary endpoint was change from baseline at 12 months in liver iron concentration (LIC), assessed by R2* magnetic resonance imaging (MRI). The least squares mean (standard error) change in LIC was -4.04 (0.48) mg/g dry weight for deferiprone vs -4.45 (0.57) mg/g dry weight for deferoxamine, with noninferiority of deferiprone to deferoxamine demonstrated by analysis of covariance (least squares mean difference 0.40 [0.56]; 96.01% confidence interval, -0.76 to 1.57). Noninferiority of deferiprone was also shown for both cardiac T2* MRI and serum ferritin. Rates of overall adverse events (AEs), treatment-related AEs, serious AEs, and AEs leading to withdrawal did not differ significantly between the groups. AEs related to deferiprone treatment included abdominal pain (17.1% of patients), vomiting (14.5%), pyrexia (9.2%), increased alanine transferase (9.2%) and aspartate transferase levels (9.2%), neutropenia (2.6%), and agranulocytosis (0.7%). The efficacy and safety profiles of deferiprone were acceptable and consistent with those seen in patients with transfusion-dependent thalassemia. This trial study was registered at www:// as #NCT02041299.

Pennell, D. J., J. B. Porter, M. D. Cappellini, L. L. Chan, A. El-Beshlawy, Y. Aydinok, H. Ibrahim, C. - K. Li, V. Viprakasit, M. S. Elalfy, et al., "Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.", Haematologica, vol. 97, issue 6, pp. 842-8, 2012 Jun. Abstract

BACKGROUND: Prospective data on cardiac iron removal are limited beyond one year and longer-term studies are, therefore, important.

DESIGN AND METHODS: Seventy-one patients in the EPIC cardiac substudy elected to continue into the 3(rd) year, allowing cardiac iron removal to be analyzed over three years.

RESULTS: Mean deferasirox dose during year 3 was 33.6 ± 9.8 mg/kg per day. Myocardial T2*, assessed by cardiovascular magnetic resonance, significantly increased from 12.0 ms ± 39.1% at baseline to 17.1 ms ± 62.0% at end of study (P<0.001), corresponding to a decrease in cardiac iron concentration (based on ad hoc analysis of T2*) from 2.43 ± 1.2 mg Fe/g dry weight (dw) at baseline to 1.80 ± 1.4 mg Fe/g dw at end of study (P<0.001). After three years, 68.1% of patients with baseline T2* 10 to <20 ms normalized (≥ 20 ms) and 50.0% of patients with baseline T2* >5 to <10 ms improved to 10 to <20 ms. There was no significant variation in left ventricular ejection fraction over the three years. No deaths occurred and the most common investigator-assessed drug-related adverse event in year 3 was increased serum creatinine (n = 9, 12.7%).

CONCLUSIONS: Three years of deferasirox treatment along with a clinically manageable safety profile significantly reduced cardiac iron overload versus baseline and normalized T2* in 68.1% (32 of 47) of patients with T2* 10 to <20 ms.

Shaban, H. E., I. B. Helal, I. M. E. M. husseiny, M. M. Shamseldean, and A. I. Seif, "Defensive reactions of Periplaneta americana (blattodea: blattidae) adults against Steinernema sp. 2d (Rhabditida).", Egyptian Journal of Experimental Biology (Zoology)., vol. 6, issue 2, pp. 263-271., 2010. Abstract
Hussein, Z., S. Abd El-Aty, G. Elmeniawy, and E. Mahgoub, "Defects of motor performance in children with different types of specific learning disability", Drug Invention Today, vol. 14, issue 2, pp. 302-307, 2020. lbhth_lthny.pdf
AbdelHak, S. I., T. Hatem, E. E. Khalil, and W. AbdelMaksoud, "Defects Evolution in High Efficiency Third Generation Photovoltaic Cells", WREC XVII, December 2016, Bahrain, WORLD CONGRESS ON Renewable Energy, pp. 1-10, 2016.
Lancaster, M. A., D. J. Gopal, J. Kim, S. N. Saleem, J. L. Silhavy, C. M. Louie, B. E. Thacker, Y. Williams, M. S. Zaki, and J. G. Gleeson, "Defective Wnt-dependent Cerebellar Midline Fusion in a Mouse Model of Joubert Syndrome", Nature Medicine, 2011. Abstractcu_pdf.pdf

The ciliopathy Joubert syndrome is marked by cerebellar vermis hypoplasia, a phenotype for which the pathogenic mechanism is unclear. To investigate Joubert syndrome pathogenesis, we have examined mice with mutated Ahi1, the first identified Joubert syndrome-associated gene. These mice show cerebellar hypoplasia with a vermis-midline fusion defect early in development. This defect is concomitant with expansion of the roof plate and is also evident in a mouse mutant for another Joubert syndrome-associated gene, Cep290. Furthermore, fetal magnetic resonance imaging (MRI) of human subjects with Joubert syndrome reveals a similar midline cleft, suggesting parallel pathogenic mechanisms. Previous evidence has suggested a role for Jouberin (Jbn), the protein encoded by Ahi1, in canonical Wnt signaling. Consistent with this, we found decreased Wnt reporter activity at the site of hemisphere fusion in the developing cerebellum of Ahi1-mutant mice. This decrease was accompanied by reduced proliferation at the site of fusion. Finally, treatment with lithium, a Wnt pathway agonist, partially rescued this phenotype. Our findings implicate a defect in Wnt signaling in the cerebellar midline phenotype seen in Joubert syndrome that can be overcome with Wnt stimulation.

Lancaster, M. A., D. J. Gopal, J. Kim, S. N. Saleem, J. L. Silhavy, C. M. Louie, B. E. Thacker, Y. Williams, M. S. Zaki, and J. G. Gleeson, "Defective Wnt-dependent cerebellar midline fusion in a mouse model of Joubert syndrome", Nature Medicine, vol. 17, no. 6: Nature Publishing Group, pp. 726–731, 2011. Abstract
Lancaster, M. A., D. J. Gopal, J. Kim, S. N. Saleem, J. L. Silhavy, C. M. Louie, B. E. Thacker, Y. Williams, M. S. Zaki, and J. G. Gleeson, "Defective Wnt-dependent cerebellar midline fusion in a mouse model of Joubert syndrome", Nature medicine, vol. 17, no. 6: Nature Publishing Group, pp. 726–731, 2011. Abstract
El-Shaarawy, H. B., F. Coccetti, R. Plana, E. M. Said, and E. A. Hashish, "Defected Ground Structure (DGS) and uniplanar compact-photonic band gap (UC-PBG) structures for reducing the size and enhancing the out-of-band rejection of microstrip bandpass ring resonator filters", WSEAS Transactions on Communications, vol. 11, issue 7, pp. 1112 – 1121, 2008.
Annaby, M. H., S. H. Basha, and Y. M. Fouda, "Defect detection methods using boolean functions and the φ-coefficient between bit-plane slices", Optics and Lasers in Engineering, 2020.
Alaa, A., and Y. Fahmy, "Defeating the Eavesdropper: On the Achievable Secrecy Capacity Using Reconfigurable Antennas", Wireless Personal Communications, vol. 91, issue 2, pp. 729–738, 2016. Abstract


Zaki, S. A., H. Zhu, M. A. Fakih, A. R. Sayed, and J. Yao, "Deep‐learning–based method for faults classification of PV system", IET Renewable Power Generation, vol. 15, issue 1, pp. 193-205, 2021. Abstract
sherif et Al, A., "DeepOnKHATT: An End-to-End Arabic Online Handwriting Recognition System", International Journal of Pattern Recognition and Artifcial Intelligence, vol. 35, pp. 2153006-2153027, 2021.
Abdalla, M., A. Hendawi, H. M. O. Mokhtar, N. ElGamal, J. Krumm, and M. Ali, "DeepMotions: A Deep Learning System For Path Prediction Using Similar Motions.", IEEE Access, vol. 8, pp. 23881 - 23894, 2020/01/15. Abstract